Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

被引：12

作者：

Allan, John N.

Shanafelt, Tait

Wiestner, Adrian

Moreno, Carol

O'Brien, Susan M.

Braggio, Esteban

Liu, Emily

Dean, James P.

Lai, Dominic

Ahn, Inhye E.

机构：

来源：

BLOOD | 2020年 / 136卷

关键词：

D O I：

10.1182/blood-2020-134431

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] ANALYSIS OF TP53 MUTATION IN A LARGE COHORT OF CLL PATIENTS BEFORE FIRST-LINE TREATMENT: ANALYSIS OF THE GENETIC PROFILE WITHIN THE CLL4 TRIAL (F vs FC) OF THE GCLLSG [J].

Zenz, T. ;

Denzel, T. ;

Haebe, S. ;

Winkler, D. ;

Buehler, A. ;

Busch, R. ;

Eichhorst, B. ;

Hallek, M. ;

Doehner, H. ;

Stilgenbauer, S. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 :216-216

[32] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data [J].

Jain, Nitin ;

Keating, Michael J. ;

Thompson, Philip A. ;

Ferrajoli, Alessandra ;

Senapati, Jayastu ;

Burger, Jan A. ;

Borthakur, Gautam ;

Takahashi, Koichi ;

Estrov, Zeev E. ;

Konopleva, Marina ;

Sasaki, Koji ;

Kadia, Tapan M. ;

Pemmaraju, Naveen ;

Daver, Naval ;

Jabbour, Elias ;

DiNardo, Courtney D. ;

Alvarado, Yesid ;

Yilmaz, Musa ;

Bose, Prithviraj ;

Ohanian, Maro ;

Kanagal-Shamanna, Rashmi ;

Patel, Keyur ;

Jorgensen, Jeffrey L. ;

Wang, Sa A. ;

Nassar, Sameh ;

Garg, Naveen ;

Hwang, Hyunsoo ;

Wang, Xuemei ;

Cruz, Nichole ;

Ayala, Ana ;

Plunkett, William ;

Kantarjian, Hagop ;

Gandhi, Varsha ;

Wierda, William G. .

BLOOD, 2022, 140

[33] Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial [J].

Zenz, Thorsten ;

Haebe, Sonja ;

Denzel, Tina ;

Mohr, Julia ;

Winkler, Dirk ;

Buehler, Andreas ;

Sarno, Antonio ;

Groner, Silja ;

Mertens, Daniel ;

Busch, Raymonde ;

Hallek, Michael ;

Doehner, Hartmut ;

Stilgenbauer, Stephan .

BLOOD, 2009, 114 (13) :2589-2597

[34] Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation [J].

Ermann, Daniel A. ;

Vardell, Victoria A. ;

Bock, Allison M. ;

Horns, Joshua J. ;

Shah, Harsh R. ;

Fitzgerald, Lindsey ;

Hu, Boyu ;

Kittai, Adam S. ;

Stephens, Deborah M. .

BLOOD, 2024, 144 :1864-1865

[35] Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation [J].

Barrientos, Jacqueline Claudia ;

Coutre, Steven ;

De Vos, Sven ;

Flinn, Ian ;

Wagner-Johnston, Nina D. ;

Schreeder, Marshall T. ;

Sharman, Jeff Porter ;

Boyd, Thomas E. ;

Rai, Kanti Roop ;

Leonard, John ;

Sorensen, Bess ;

Viggiano, Anthony ;

Jahn, Thomas Michael ;

Furman, Richard R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[36] Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial [J].

Gonzalez, David ;

Martinez, Pilar ;

Wade, Rachel ;

Hockley, Sarah ;

Oscier, David ;

Matutes, Estella ;

Dearden, Claire E. ;

Richards, Sue M. ;

Catovsky, Daniel ;

Morgan, Gareth J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2223-2229

[37] A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation [J].

Brown, Jennifer R. ;

Eichhorst, Barbara F. ;

Ghia, Paolo ;

Kater, Arnon P. ;

Li, Jianyong ;

Khurana, Sudha ;

Elhamy, Mostafa ;

Wang, Min Hui ;

Seymour, John F. .

BLOOD, 2019, 134

[38] TP53 MUTATION IN THE ABSENCE OF 17P DELETION DEFINES A GROUP OF PATIENTS WITH POOR OUTCOME IN CLL: ANALYSIS WITHIN THE CLL4 TRIAL (F VS. FC) OF THE GCLLSG [J].

Zenz, T. ;

Eichhorst, B. ;

Busch, R. ;

Denzel, T. ;

Haebe, S. ;

Winkler, D. ;

Buehler, A. ;

Hallek, M. ;

Doehner, H. ;

Stilgenbauer, S. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 :199-199

[39] Genomic Mechanisms of 17p / TP53 Loss in Primary "ultra High-risk" and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial [J].

Teleanu, Veronica ;

Edelmann, Jennifer ;

Haferlach, Claudia ;

Ibach, Stefan ;

Tausch, Eugen ;

Bloehdorn, Johannes ;

Leblond, Veronique ;

Cymbalista, Florence ;

Delmer, Alain ;

Hallek, Michael ;

Doehner, Hartmut ;

Stilgenbauer, Stephan .

BLOOD, 2014, 124 (21)

[40] Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation [J].

Coutre, Steven E. ;

Leonard, John P. ;

Barrientos, Jacqueline C. ;

De Vos, Sven ;

Flinn, Ian ;

Furman, Richard R. ;

Brown, Jennifer R. ;

Wagner-Johnston, Nina ;

Benson, Don M., Jr. ;

Schreeder, Marshall T. ;

Sharman, Jeff P. ;

Boyd, Thomas ;

Spurgeon, Stephen ;

Zelenetz, Andrew D. ;

Lamanna, Nicole ;

Kipps, Thomas J. ;

Kahl, Brad S. ;

Bello, Celeste M. ;

Burger, Jan A. ;

Rai, Kanti R. ;

Dansey, Roger ;

Kim, Yeonhee ;

Holes, Leanne M. ;

Lazarov, Mirella ;

Dubowy, Ronald L. ;

O'Brien, Susan M. .

BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →